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cedures are 81% (95% CI: 73%-89%; p< 0.0001) more likely to suffer an anastomotic 
leak than laparoscopic procedures. ConClusions: In colorectal resections, anasto-
motic leaks are associated with a longer LOS, an increased likelihood of readmission 
during the 30-day post-operative period and an incremental economic burden of 
$13,797 per patient during the index hospitalization.
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objeCtives: The objective of this study was to determine the health care burden 
associated with breast cancer in the Medicaid population in terms of health care 
use and costs associated with the condition. Methods: This study used the 2006-
2008 Medicaid analytic extract files for 39 states in the United States. The target 
population included recipients aged 18-64 years who were continuously enrolled 
in Medicaid during 2006-2008. Breast cancer-related health care utilization during 
2007-2008 in terms of inpatient, outpatient, and emergency room visits and treat-
ment use was determined for women with breast cancer. The excess health care 
burden attributable to breast cancer during 2007-2008 was determined by comparing 
all-cause health care use and costs between Medicaid recipients with breast cancer 
and a matched control group of recipients without breast cancer. Generalized linear 
model with log link and Poisson distribution was used for multivariable comparison 
of all-cause costs between recipients with and without breast cancer. Results: We 
identified 34,198 cases of breast cancer in the Medicaid population. Breast cancer-
related inpatient, outpatient, and emergency room visits were higher among women 
aged 30-39 and 40-49 years and ethnic minorities as compared to women aged 18-29, 
50-59, and 60-64 years and whites respectively (p< 0.0001). Hormonal therapy was 
the most commonly used treatment (26.8% and 28.1% of the recipients in 2007 and 
2008 respectively). The all-cause inpatient, outpatient, and emergency room visits 
were higher in recipients with breast cancer as compared to those without breast 
cancer (p< 0.0001). In the multivariable analysis, recipients with breast cancer were 
found to have ~23.4% higher costs per year as compared to recipients without breast 
cancer (estimate: 0.2104, 95% confidence interval: 0.1955–0.2252). ConClusions: 
Breast cancer is associated with a considerable health care burden in the Medicaid 
population. Health care use and costs were considerably greater among recipients 
with breast cancer as compared to those without breast cancer.
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objeCtives: Gastric cancer (GC) is the fourth most common cancer globally and 
an important cause of morbidity and mortality in the US. Prognosis is poor, treat-
ment options are limited, and there has been little progress in improving outcomes 
over the last 25 years. The objective of the study was to describe the demographic 
and clinical characteristics, mortality, health care utilization and cost of patients 
with gastric cancer. Methods: A retrospective cohort study on GC and non-cancer 
patients was conducted using the HealthCore Integrated Research Environment dur-
ing 2007-2012. GC cases were ≥ 18 years, had at least 2 diagnosis codes for GC within 
60 days (first diagnosis was index) and had 12 months pre-index history. GC patients 
were matched 1-to-10 with patients having no diagnosed cancer on age, gender, 
health plan type, and geographic region. Descriptive analyses were performed for 
health care utilization and cost, and mortality. Stratified analyses were conducted by 
patient age, site of cancer and coding for metastatic disease. Results: There were 
1,668 GC cases and 16,680 cancer free patients. Mean age was 66 years and 65% of 
patients were male. Patients with GC incurred more than ten times the health care 
costs than those without cancer ($96,571 vs. $8,338) during the follow-up period, 
particularly those with advanced disease ($131,663). When including only those 
costs specifically linked to gastric cancer, these differences remain. Three-year sur-
vival was 45% and 94% in patients with GC and without cancer, respectively (hazard 
ratio= 14.9). Chemotherapy and/or chemo-radiation without curative surgery was 
the most common treatment seen in GC patients during the first 18 months of fol-
low-up (53%); trastuzumab use was only detected in 17 patients. ConClusions: GC 
represents a significant burden both to the individual and health care system, with 
considerably higher resource use and costs than matched patients without cancer.
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objeCtives: To estimate the 1-year burden following TKI treatment failure of first-
line (1L) imatinib or first/second/third-line (1L/2L/3L) dasatinib or nilotinib in CML 
from a US managed care perspective. Methods: Treatment episodes initiating 
a TKI of interest (index TKI) during 6/2008-12/2011 were identified from the IMS 
PharMetrics Plus Health Plan Claims Database for adult patients with CML diagnosis 
(ICD-9-CM 205.1x), 120-days pre-index continuous enrollment (CE) and no clinical 
trial participation. Episodes experiencing treatment failure, defined as switch to a 
non-index TKI or discontinuation of index TKI (gap of ≥ 60 days), and with 1-year CE 
post-failure, were analyzed. LOT was determined by number of unique TKIs used 
pre-index (1L:0, 2L:1, 3L:2). All-cause medical resource utilization (MRU) and costs 
(2012 USD) in the 1-year post-failure were assessed by LOT. Adjusted relative rates 
(RR) for mean MRU and costs for 2L vs. 1L were estimated via generalized linear 
models. Results: 706 episodes (1L:518, 2L:180, 3L:8) were identified (mean age= 53 
region. Determinants of the difference in total costs include hospital expense and 
drug price. ConClusions: In a large, randomized trial in RCC, patients receiving 
pazopanib were less expensive compared to patients receiving sunitinib.
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objeCtives: Androgen ablation (ADT) maintenance is recommended during castra-
tion-resistant prostate cancer; however the overall cost of medications during this 
phase is dramatically increasing with ADT accounting for almost 21% of the total 
cost. The objective of this study was to perform a cost comparison of different forms 
of ADT, including luteinizing hormone releasing hormone agonists (LHRHa) medi-
cations and surgical castration, over the phase of metastatic castration-resistant 
prostate cancer (mCRPC). Methods: Two Markov models were developed in order 
to simulate survival in mCRPC, and the cost of ADT as per Quebec’s public health 
care system. The models include recently approved additional lines of treatment 
after and/or before docetaxel (i.e. abiraterone and cabazitaxel). Survival was based 
on clinical trial results and clinical practice guidelines found in a literature review. 
Costs are in Canadian dollars ($). Results: The mean cost of ADT per patient in 
mCRPC over an average period of 28.1 months was estimated at: $1,413 for surgical 
castration, $8,346 for Leuprolide (Eligard), $8,514 for Triptorelin (Trelstar), $9,891 
for Buserelin (Suprefact Depot), $10,032 Leuprolide (Lupron Depot), and $10,172 for 
Goserelin (Zoladex). The corresponding values obtained with the alternate model 
(which includes abiraterone initiation prior to docetaxel therapy) over a 37.2 months 
were: $1,413, $11,078, $11,302, $13,130, $13,316 and $13,503, respectively. For each 
annual Canadian cohort of 4,000 mCRPC patients, for a 28.1 months period, the 
total cost of ADT was estimated at $ 5.6 million for surgical castration, and between 
$33.4 and $40.7 million for LHRHa therapy. For a 37.2 months period, the total cost 
for surgical castration remained the same and was between $44.3 and $54.0 million 
for LHRHa therapy. ConClusions: Our study estimates the costs associated with 
the use of different ADT in mCRPC. Increasing the use of least costly forms of ADT 
will result in potential cost savings during the mCRPC phase.
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objeCtives: The direct medical costs of melanoma patients by disease stage have 
not been well reported. This study used Surveillance, Epidemiology, and End Results 
(SEER) – Medicare linked data to examine costs in patients with melanoma, by 
disease stage. Methods: All patients diagnosed with stage IIIB, IIIC, M1a, M1b, 
or M1c melanoma in SEER-Medicare data 2004 - 2009 were included in the study. 
Follow up period was ≥ 1 month, starting from the date of the first diagnosis of 
stage IIIB-M1c melanoma until death or end of the study period. All-cause medical 
costs were standardized as per patient per month (PPPM) and adjusted to 2013 dol-
lars. Results: A total of 1263 melanoma patients met the study criteria, with 43.5% 
at Stage IIIB, 23.0% IIIC, 11.6% M1a, 8.9% M1b, and 12.9% M1c. Their mean age was 
75.0 (standard deviation (SD) 9.3), 65.3% was male, and mean follow up length was 
37.5 (SD 22.7) months. The mean PPPM costs were $1851 (SD $2168) for patients with 
Stage IIIB, $2557 (SD $2759) for Stage IIIC, $2278 (SD $2722) for Stage M1a, $3203 (SD 
$3582) for Stage M1b, and $4317 (SD $3910) for Stage M1c. Across all disease stages, 
outpatient and inpatients costs were the primary cost drivers, outpatient costs 
accounting for 37.5% (for patients at Stage M1c) to 47.7% (for patients at Stage IIIB), 
while inpatient costs accounting for 36.1% (M1b) to 40.9% (M1c) of the total medi-
cal costs. The other cost categories were hospice stay (6.3% - 16.5% of total medical 
costs), skilled nursing facility (2.8% - 7.8%), home health care (0.9% - 1.6%), and emer-
gency room visits (0.9% – 1.2%). ConClusions: Patients at later stages had higher 
total medical costs than patients at earlier stages. Treatments that prevent or delay 
disease progression to later stages could potentially reduce total medical costs.
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objeCtives: Anastomotic leaks following colorectal resections result in increased 
morbidity, mortality, and costs. These types of surgeries are performed via an open 
or laparoscopic approach. This analysis compares the total health care utilization 
and reimbursement by comparing colorectal resections with and without anas-
tomotic leak complications. Methods: This study utilized administrative health 
claims data from MarketScan® Commercial and Medicare databases from January 
2009 to December 2011. Patients undergoing colorectal resections with an anasto-
mosis were identified from ICD-9 procedure codes. An algorithm based on clinical 
expertise was developed which utilized relevant ICD-9 diagnosis codes to identify 
patients with suspected anastomotic leaks. A multivariate logistic regression analy-
sis for the binary outcome of anastomotic leak (yes or no) was performed analyzing 
length of stay (LOS), rehospitalization, and reimbursement. Reimbursement and 
LOS were modeled with generalized linear models with a gamma distribution and 
log-link. Results: A total of 78,622 colorectal resections were identified, including 
73,945 with a colorectal resection primary code (94.1%) and 4,677 with an anastomo-
sis primary code and secondary resection code (5.9%). Procedures with anastomotic 
leaks are associated with longer LOS than without anastomotic leaks (9.5 versus 
6.2 days; p< 0.0001) and are 124% (95% CI, 111% to 137%; p< 0.0001) more likely to 
be readmitted within 30 days. Health care expenditures during the index inpatient 
stay for patients with anastomotic leaks are higher than for those without ($43,792 
versus $29,995; p< 0.0001). Multivariable logistic regression showed that open pro-
